TERPS Trial for de Novo Oligometastic Prostate Cancer
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Trial Details
- NCT ID
- NCT05223803
- Phase
- PHASE2
- Sponsor
- University of Maryland, Baltimore
- Status
- RECRUITING
- Cancer Type
- Prostate Cancer
- Interventions
- Prostate radiation (XRT)
- Systemic Therapy
- Stereotactic ablative radiation therapy (SABR)
- Locations (sample)
- La Jolla, California, United States|32.84727,-117.2742
- Kansas City, Kansas, United States|39.11417,-94.62746
- Baltimore, Maryland, United States|39.29038,-76.61219
- Baltimore, Maryland, United States|39.29038,-76.61219
- Bel Air, Maryland, United States|39.53594,-76.34829
Key Eligibility Criteria
- Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone or soft tissue (with at least one bone metastasis) deve…
- CT or MRI scan within 6 months of enrollment
- Bone scan within 6 months of enrollment
- Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternat…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Prostate Cancer Trials on Trialify →